Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.

Publication ,  Journal Article
Jones, WS; Mulder, H; Wruck, LM; Pencina, MJ; Kripalani, S; Muñoz, D; Crenshaw, DL; Effron, MB; Re, RN; Gupta, K; Anderson, RD; Pepine, CJ ...
Published in: N Engl J Med
May 27, 2021

BACKGROUND: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy. METHODS: Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis. The primary safety outcome was hospitalization for major bleeding, also assessed in a time-to-event analysis. RESULTS: A total of 15,076 patients were followed for a median of 26.2 months (interquartile range [IQR], 19.0 to 34.9). Before randomization, 13,537 (96.0% of those with available information on previous aspirin use) were already taking aspirin, and 85.3% of these patients were previously taking 81 mg of daily aspirin. Death, hospitalization for myocardial infarction, or hospitalization for stroke occurred in 590 patients (estimated percentage, 7.28%) in the 81-mg group and 569 patients (estimated percentage, 7.51%) in the 325-mg group (hazard ratio, 1.02; 95% confidence interval [CI], 0.91 to 1.14). Hospitalization for major bleeding occurred in 53 patients (estimated percentage, 0.63%) in the 81-mg group and 44 patients (estimated percentage, 0.60%) in the 325-mg group (hazard ratio, 1.18; 95% CI, 0.79 to 1.77). Patients assigned to 325 mg had a higher incidence of dose switching than those assigned to 81 mg (41.6% vs. 7.1%) and fewer median days of exposure to the assigned dose (434 days [IQR, 139 to 737] vs. 650 days [IQR, 415 to 922]). CONCLUSIONS: In this pragmatic trial involving patients with established cardiovascular disease, there was substantial dose switching to 81 mg of daily aspirin and no significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg and those assigned to 325 mg of aspirin daily. (Funded by the Patient-Centered Outcomes Research Institute; ADAPTABLE ClinicalTrials.gov number, NCT02697916.).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

May 27, 2021

Volume

384

Issue

21

Start / End Page

1981 / 1990

Location

United States

Related Subject Headings

  • Stroke
  • Secondary Prevention
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Medication Adherence
  • Male
  • Humans
  • Hospitalization
  • Hemorrhage
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jones, W. S., Mulder, H., Wruck, L. M., Pencina, M. J., Kripalani, S., Muñoz, D., … ADAPTABLE Team, . (2021). Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med, 384(21), 1981–1990. https://doi.org/10.1056/NEJMoa2102137
Jones, W Schuyler, Hillary Mulder, Lisa M. Wruck, Michael J. Pencina, Sunil Kripalani, Daniel Muñoz, David L. Crenshaw, et al. “Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.N Engl J Med 384, no. 21 (May 27, 2021): 1981–90. https://doi.org/10.1056/NEJMoa2102137.
Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 May 27;384(21):1981–90.
Jones, W. Schuyler, et al. “Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.N Engl J Med, vol. 384, no. 21, May 2021, pp. 1981–90. Pubmed, doi:10.1056/NEJMoa2102137.
Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, Crenshaw DL, Effron MB, Re RN, Gupta K, Anderson RD, Pepine CJ, Handberg EM, Manning BR, Jain SK, Girotra S, Riley D, DeWalt DA, Whittle J, Goldberg YH, Roger VL, Hess R, Benziger CP, Farrehi P, Zhou L, Ford DE, Haynes K, VanWormer JJ, Knowlton KU, Kraschnewski JL, Polonsky TS, Fintel DJ, Ahmad FS, McClay JC, Campbell JR, Bell DS, Fonarow GC, Bradley SM, Paranjape A, Roe MT, Robertson HR, Curtis LH, Sharlow AG, Berdan LG, Hammill BG, Harris DF, Qualls LG, Marquis-Gravel G, Modrow MF, Marcus GM, Carton TW, Nauman E, Waitman LR, Kho AN, Shenkman EA, McTigue KM, Kaushal R, Masoudi FA, Antman EM, Davidson DR, Edgley K, Merritt JG, Brown LS, Zemon DN, McCormick TE, Alikhaani JD, Gregoire KC, Rothman RL, Harrington RA, Hernandez AF, ADAPTABLE Team. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 May 27;384(21):1981–1990.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

May 27, 2021

Volume

384

Issue

21

Start / End Page

1981 / 1990

Location

United States

Related Subject Headings

  • Stroke
  • Secondary Prevention
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Medication Adherence
  • Male
  • Humans
  • Hospitalization
  • Hemorrhage